Christoffer W. Tornoe

Articles by Christoffer W. Tornoe

PK in Late Phase Trials

ByRajnikanth Madabushi,Jeffry Florian,Fang Li,Christoffer W. Tornoe,Christine Garnett,Hao Zhu,Yaning Wang, PhD,Nitin Mehrotra,Anshu Marathe,Jiang Liu,Venkatesh A. Bhattaram,Pravin R. Jadhav,Jogarao V. Gobburu,Joo-Yeon Lee,Kevin Krudys,Justin C. Earp

February 1st 2012

Applied Clinical Trials

Collecting PK data in late phase trials led to alleviating additional trials, drug approval, and better dosing.

Latest Updated Articles

PK in Late Phase Trials
February 1st 2012

Trending on Applied Clinical Trials Online

Recruitment in the Age of AI: Q&A with John Worden, Javara

What It Actually Means to Embed the Patient Voice in Trial Design

Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable

Why Seizure Counts Alone Can't Define Success in Epilepsy Trials

What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale